Results of retroperitoneal lymph node dissection after chemotherapy in patients with pure seminoma in the orchidectomy specimen but elevated serum alpha-fetoprotein.
OBJECTIVE
To determine the incidence of necrosis, teratoma, and active cancer in specimens at retroperitoneal lymph node dissection (RPLND) after chemotherapy in patients who presented with a pure seminoma primary tumour and an elevated serum alpha-fetoprotein (AFP) level at diagnosis who underwent surgery.


METHODS
A retrospective review of the Indiana University testis cancer database from 1980 to 2004 was performed to identify all patients with metastasic germ cell cancer, pure seminoma in the orchidectomy specimen, and an elevated AFP level. In all, 42 patients were identified; two with nonseminomatous germ cell cancer in the contralateral testicle were excluded.


RESULTS
RPLND pathology in the 40 patients showed necrosis in 13 (32.5%), teratoma in 12 (30%), and cancer in 15 (37.5%). The histological subtype of the 15 cancer specimens at RPLND was pure seminoma in two, embryonal in three, yolk sac in seven, variant in one, and mixed elements in two (one with seminoma and yolk sac, and one with embryonal and variant). In all, 20 patients presented with a serum AFP level of <1000 microg/mL with nine (45%) having teratoma only in the retroperitoneum in contrast to 20 patients with an AFP level of >1000 microg/mL with three (15%) having teratoma only in the retroperitoneum (P = 0.04). The level of serum AFP did not predict for active cancer in the retroperitoneum (P = 0.5).


CONCLUSIONS
RPLND in patients after chemotherapy who presented with pure seminoma in the orchidectomy specimen and an elevated AFP do not have a high probability of finding necrosis only in the RPLND specimen. In fact, the prevalence of persistent cancer is higher compared with the general group of patients that have RPLND after chemotherapy.
Peterson
Matthew
M
Department of Urology, Indiana University School of Medicine, Indianapolis, IN, USA.
Beck
Stephen
S
Bihrle
Richard
R
Einhorn
Lawrence
L
Foster
Richard
R
D003131:Combined Modality Therapy; D006801:Humans; D008197:Lymph Node Excision / Q000379:methods; D008297:Male; D009919:Orchiectomy / Q000379:methods; D012186:Retroperitoneal Neoplasms / Q000556:secondary* / Q000601:surgery; D012189:Retrospective Studies; D018239:Seminoma / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery; D013724:Teratoma / Q000473:pathology; D013736:Testicular Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D000509:alpha-Fetoproteins / Q000378:metabolism*
D000509:alpha-Fetoproteins